0001104659-21-146421.txt : 20211203
0001104659-21-146421.hdr.sgml : 20211203
20211203171333
ACCESSION NUMBER: 0001104659-21-146421
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211202
FILED AS OF DATE: 20211203
DATE AS OF CHANGE: 20211203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burns John Thomas
CENTRAL INDEX KEY: 0001568734
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 211471095
MAIL ADDRESS:
STREET 1: 16760 SW UPPER BOONES FERRY RD
STREET 2: SUITE 101
CITY: PORTLAND
STATE: X1
ZIP: 97224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 6462005278
MAIL ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Galena Biopharma, Inc.
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
4
1
tm2134552-4_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-12-02
0
0001390478
SELLAS Life Sciences Group, Inc.
SLS
0001568734
Burns John Thomas
C/O SELLAS LIFE SCIENCES GROUP, INC.
7 TIMES SQUARE, SUITE 2503
NEW YORK
NY
10036
0
1
0
0
VP, Finance & Corp Controller
Common Stock
2021-12-02
4
S
0
231
6.2673
D
17644
D
Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
/s/ John Burns
2021-12-03